We are live on
!
Find out more
SFM
Sphera Funds Management Portfolio holdings
AUM
$767M
1-Year Est. Return
119.71%
This Fund
S&P 500
This Quarter
Est. Return
+8.89%
1 Year Est. Return
+119.71%
3 Year Est. Return
+244.81%
5 Year Est. Return
+382.5%
10 Year Est. Return
+2,655.81%
AUM
$1.02B
AUM Growth
+$60.4M
(+6.3%)
Cap. Flow
+$14.8M
Cap. Flow
% of AUM
1.45%
Top 10 Holdings %
Top 10 Hldgs %
49.68%
Holding
183
New
37
Increased
35
Reduced
45
Closed
53
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BCOM
B Communications Ltd
BCOM
|
+$95.7M |
| 2 |
Biogen
BIIB
|
+$20.4M |
| 3 |
CELG
Celgene Corp
CELG
|
+$10.3M |
| 4 |
CXRX
Concordia International Corp. Common Stock
CXRX
|
+$7.22M |
| 5 |
ATXS
Astria Therapeutics
ATXS
|
+$5.62M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ENDP
Endo International plc
ENDP
|
+$18.8M |
| 2 |
Teva Pharmaceutical Industries Limited
TEVA
|
+$13.9M |
| 3 |
ASPX
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
|
+$12.5M |
| 4 |
Amgen
AMGN
|
+$9.61M |
| 5 |
iShares Russell 2000 ETF
IWM
|
+$6.98M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 54.64% |
| 2 | Miscellaneous | 38.08% |
| 3 | Technology | 3.95% |
| 4 | Utilities | 1.35% |
| 5 | Industrials | 0.96% |
Similar funds
ISWM
ACP
NIM
ACM
CBT
SPIA
CNB
HI
Sphera Funds Management's Q2 2015 Portfolio in Review
As of Q2 2015, Sphera Funds Management held 183 positions worth $1.02B, up 6.3% from $961M the previous quarter. Its ten largest holdings account for 50% of the portfolio.
Sphera Funds Management's Q2 2015 filing shows 37 new, 35 increased, 45 reduced and 53 closed positions. Its largest new stake was B Communications Ltd: 5,977,000 shares worth $6.45M. The largest sale was Endo International plc, an estimated $18.8M.
By sector, the portfolio is most concentrated in Healthcare at 55% of assets, down from 59% a quarter earlier, followed by Miscellaneous and Technology.
- Sphera Funds Management's largest Q2 2015 buy was B Communications Ltd: 5,977,000 shares worth $6.45M.
- Sphera Funds Management added most to Biogen in Q2 2015, an estimated $20.4M increase.
- Sphera Funds Management's biggest Q2 2015 reduction was Teva Pharmaceutical Industries Limited, cutting an estimated $13.9M.
- Sphera Funds Management fully exited Endo International plc in Q2 2015, selling an estimated $18.8M.
- Sphera Funds Management's ten largest holdings make up 50% of its $1.02B portfolio in Q2 2015.
- Sphera Funds Management opened 37 new positions and closed 53 in Q2 2015.
- Sphera Funds Management's portfolio value rose 6.3% quarter-over-quarter to $1.02B.
Based on Sphera Funds Management's 13F filing for Q2 2015, filed 6 Aug 2015.